Health and Healthcare Systems

COVID-19: A new drug is tested, and other top science stories of the week

Workers of the ecology and environment bureau collect samples from the sewage system of a hospital following an outbreak of the novel coronavirus in the country, in Xinle, Hebei province, China February 8, 2020. Picture taken February 8, 2020

Could wastewater testing help scientists track outbreaks more accurately? Image: REUTERS

Greta Keenan
Lead, Strategic Impact and Communications, World Economic Forum Geneva
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:


  • The COVID-19 pandemic has infected over 1.6 million people worldwide.
  • Scientists are testing a new treatment that tackles human cells, rather than the virus.

Low antibody levels raise concerns over immunity

Researchers at Fudan University in Shanghai analysed blood samples from 175 recovered coronavirus patients after they were discharged from hospital and found surprisingly low levels of antibodies against the virus.

Around 30% of patients had antibody levels that were so low, researchers suspect they might not be protected against reinfection.

Have you read?

The fear is that if a proportion of the population does not build up immunity to the virus, herd immunity could be compromised. Additionally, scientists developing vaccines would need to consider how to generate a significant and lasting antibody response to provide sufficient protection.

The preliminary results are not yet published in a journal, and further research is necessary to examine whether individuals with low levels of antibodies are at risk of reinfection.

Drug that targets us, not the virus, enters clinical trials

This week marked the beginning of another clinical trial of a potential COVID-19 therapy, but rather unusually, this one targets human cells rather than the virus.

An illustration shows how the virus enters a human host cell Image: Reuters

Last month, scientists showed that the drug, camostat mesylate, can prevent the novel coronavirus, SARS-CoV-2, from infecting lung cells in the lab. Viruses rely on the machinery inside human “host” cells to survive and replicate, so preventing the virus from entering human cells could stop the virus in its tracks.

It normally takes years before drugs can enter human clinical trials, but because camostat mesylate is already approved for use in some patients with pancreatitis – a potentially fatal inflammation of the pancreas – scientists were able to start trials much sooner.

It isn’t yet known whether the drug will reach the lung cells of that patients that the virus targets, but the researchers at Aarhus University in Denmark who are conducting the trial hope to know whether the drug is effective within three months.


Sewage could help track the outbreak

Sewage treatment facilities hit the headlines this week as it transpired that SARS-CoV-2 genetic material — viral RNA — appears in wastewater, raising hopes of a new way to track the severity of the outbreak.

It is hoped that wastewater testing could also be used as an early-warning system of a second wave of infections, and help governments make decisions about when to implement and loosen lockdown measures.

More than a dozen research groups worldwide have started analysing wastewater for the new coronavirus to estimate the total number of infections in a community, given that many people will not experience severe symptoms, or be tested.

Studies have shown that viral RNA can appear in faeces within three days of infection, giving a much closer to real-time analysis of infection rate, compared to clinical tests which can have a lag time of weeks.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Gender and health equity will only come with universal access to eye health – here's why

Dr. Princess Ifeoma Ike

May 24, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum